Stay updated with breaking news from Cll. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BTK degrader NX-5948 has been granted Fast Track designation by the FDA to treat some adults with relapsed or refractory chronic lymphocytic leukemia or relapsed or refractory small lymphocytic lymphoma.
Michael Choi, MD, discusses subsequent treatment options for patients with relapsed/refractory chronic lymphocytic leukemia who progressed or experienced unacceptable intolerance with a prior covalent BTK inhibitor.
Oncology experts discuss findings from ELEVATE-RR and outline key considerations for combination with acalabrutinib plus obinutuzumab.
Michael Choi, MD, discusses several key considerations for the treatment of chronic lymphocytic leukemia from his presentation at a recent OncLive® State of the Science Summit™ on hematologic malignancies.
Michael Choi, MD, discusses key mechanistic differences between BTK degraders and BTK inhibitors in the management of relapsed/refractory chronic lymphocytic leukemia, , as well as highlights how this approach could address unmet needs within the CLL treatment paradigm.